# GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

> **NCT01468376** · PHASE1 · TERMINATED · sponsor: **Afexa Life Sciences Inc** · enrollment: 17 (actual)

## Conditions studied

- Impaired Glucose Tolerance

## Interventions

- **DIETARY_SUPPLEMENT:** GLU-01
- **DIETARY_SUPPLEMENT:** GLU-02
- **DIETARY_SUPPLEMENT:** GLU-03
- **DIETARY_SUPPLEMENT:** GLU-04
- **DIETARY_SUPPLEMENT:** GLU-05
- **DIETARY_SUPPLEMENT:** GLU-06

## Key facts

- **NCT ID:** NCT01468376
- **Lead sponsor:** Afexa Life Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Sponsor company was acquired and new owner chose not to proceed with clinical study
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468376, "GLU-xx Formulations in Individuals With Impaired Glucose Tolerance". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01468376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*